Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biobank Scale Pharmacogenomics Informs the Genetic Underpinnings of Simvastatin Use.

Clinical pharmacology and therapeutics - 1 Sept 2021

Wendt Frank R, Koller Dora, Pathak Gita A, Jacoby Daniel, Miller Edward J, Polimanti Renato

Abstract excerpt

Studying drug-metabolizing enzymes, encoded by pharmacogenes, may inform biological mechanisms underlying the diseases for which a medication is prescribed. Until recently, pharmacogenes could not be studied at biobank scale. In 7,649 unrelated African-ancestry (AFR) and 326,214 unrelated European-ancestry (EUR) participants from the UK Biobank, we associated pharmacogene haplotypes from 50 genes with 265 (EUR)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arylamine N-Acetyltransferase
Share to Biological Specimen Banks

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cholesterol, LDL

Share to Inactivation, Metabolic

Share to Odds Ratio

Share to Pharmacogenetics

Share to Pilot Projects

Share to Simvastatin

Source

Open in PubMed Open full text

Identifiers

PMID: 33837531
DOI: 10.1002/cpt.2260
PMCID: PMC8376807

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biobank Scale Pharmacogenomics Informs the Genetic Underpinnings of Simvastatin Use.PMID 33837531Read ↗

Biobank scale pharmacogenomics informs the genetic underpinnings of simvastatin useSemantic proximity Read ↗

Leveraging large-scale biobank EHRs to enhance pharmacogenetics of cardiometabolic disease medicationsSemantic proximity Read ↗

Leveraging large-scale biobank EHRs to enhance pharmacogenetics of cardiometabolic disease medicationsSemantic proximity Read ↗

<i>LPA</i> and <i>APOE</i> are associated with statin selection in the UK BiobankSemantic proximity Read ↗

Characterization of statin dose response in electronic medical records.Semantic proximity Read ↗

Pharmacogenetics at Scale: An Analysis of the UK Biobank.Semantic proximity Read ↗

Pharmacogenetics at scale: An analysis of the UK BiobankSemantic proximity Read ↗

Clinical implications of pharmacogenomics of statin treatmentSemantic proximity Read ↗

Genetics and personalized medicine--a role in statin therapy?Semantic proximity Read ↗

The pharmacogenomics of statins.Semantic proximity Read ↗

Drug Response Pharmacogenetics for 200,000 UK Biobank Participants.Semantic proximity Read ↗

Comparative Analysis of Atorvastatin and Rosuvastatin Side Events and Risk Factors in the UAE Multiethnic Population: Focus on Pharmacogenomic VariantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.